Lilly’s next-gen obesity drug delivers major weight loss in Phase 3 trial, but with many discontinuations +++++

Lilly’s next-gen obesity drug delivers major weight loss in Phase 3 trial, but with many discontinuations Lilly’s data comes as the next wave of obesity therapies, designed to outcompete current drugs, near the market https://www.statnews.com/2025/12/11/eli-lilly-retatrutide-weight-loss-obesity-tolerability-trial-results/ By Elaine ChenDec. 11, 2025 National Biotech Reporter Now is the time to launch mpox vaccine booster trials We need to know how to answer when people ask, ‘When should I get an mpox vaccine booster?’ https://www.statnews.com/2025/12/11/mpox-vaccine-booster-trials-research/ By Joseph Osmundson and Miguel I. ParedesDec. 11, 2025 Osmundson is a clinical assistant professor of biology at New York University and author of “Virology.” Paredes is an infectious disease epidemiologist at the University of Washington. In expert panel, FDA says ‘door is open’ for testosterone labeling revisions Academics and clinicians highlighted the importance of testosterone as a marker of male health https://www.statnews.com/2025/12/10/fda-panel-ease-access-testosterone-therapy-men/ By Annalisa MerelliDec. 10, 2025 Contributing Writer Botulism outbreak sickens more than 50 babies and expands to all ByHeart products The outbreak now includes at least 51 infants in 19 states https://www.statnews.com/2025/12/10/byheart-baby-formula-recall-botulism-outbreak-expands/ By Associated PressDec. 10, 2025 Major health insurers to skip J.P. Morgan conference, again Pricey event is skewing more biopharma, and Brian Thompson’s killing still casts a pall https://www.statnews.com/2025/12/10/insurers-skip-jpm-healthcare-conference-2026/ By Tara Bannow and Bob HermanDec. 10, 2025